8-K: iMDx Q2 2025: GraftAssureDx FDA Path on Track

Insight Molecular Diagnostics reports Q2 2025 results, reiterates FDA submission timeline for GraftAssureDx by year-end, and highlights progress in transplant and oncology pipelines.

Summary

• Reported Q2 2025 revenues of $518,000, primarily from laboratory services and initial GraftAssureIQ research-use-only (RUO) kit sales.
• Achieved a gross profit of $350,000 in Q2 2025, representing a 67.6% gross margin, an increase from 62% in Q1 2025 due to operational efficiencies.
• Operating expenses for Q2 2025 were $10.2 million, including $2.8 million in non-cash change in the fair value of contingent consideration.
• Research and development expenses increased 12% sequentially to $3.3 million, while sales and marketing expenses grew 21% sequentially to $1.5 million.
• Reported a net loss of $9.7 million, or ($0.30) per share, for Q2 2025, with a non-GAAP loss from operations of $5.98 million.
• Maintained a cash, cash equivalents, and restricted cash balance of $26.0 million at the end of Q2 2025.
• Net cash used in operating activities was $6.3 million, generally in line with the targeted quarterly average spend of $6 million.
• Reiterated the timeline for GraftAssureDx FDA submission by the end of 2025, with anticipated marketing authorization as soon as mid-2026.
• Completed a productive third meeting with the FDA on July 30, 2025, regarding GraftAssureDx.
• Clinical trial (NCT07060716) for GraftAssureDx has attracted leading transplant hospitals including Mayo Clinic, Tampa General Hospital, Cleveland Clinic, Vanderbilt University, and Intermountain Health.
• Medicare boosted reimbursement for the Lab Developed Test (LDT) version of their assay, GraftAssureCore, to $2,753 per result on May 19, 2025.
• Published new head-to-head data in June 2025 favorably comparing their digital PCR-based test kits with NGS kits.
• Presented late-breaking data at the World Transplant Congress in August 2025, showing a combined dd-cfDNA score that significantly improved positive predictive values for graft rejection.
• MolDx published a draft local coverage determination (LCD) on July 17, 2025, setting a baseline for cfDNA surveillance testing for kidney transplant patients (four tests in first year, two per year thereafter).
• Signed a non-binding development letter of intent in May 2025 with a major instrument maker for their DetermaIO immuno-oncology assay.
• Awarded U.S. Patent No. 12,359,252 B2 on July 15, 2025, covering a method for detecting colorectal cancer using circulating nucleic acid biomarkers.
• Renamed the company from Oncocyte to Insight Molecular Diagnostics Inc. and moved headquarters to Nashville, Tennessee, on June 17, 2025.

Sentiment

Score: 7

Explanation: The company reported consistent progress on its key regulatory and clinical milestones, including FDA meetings, clinical trial enrollment, and data presentations. Financial results showed gross margin expansion and cash burn in line with expectations, despite continued net losses as the company invests heavily in product development and commercialization. The reiteration of the FDA submission timeline and positive clinical data are strong indicators of execution.

Positives

• On track for GraftAssureDx FDA submission by end of 2025, with potential marketing authorization by mid-2026, reiterating prior timelines.
• Productive dialogue and guidance from the FDA, including a third pre-submission meeting, indicating positive regulatory engagement.
• Clinical trial for GraftAssureDx is attracting leading transplant hospitals, enhancing the credibility and reach of the study.
• Medicare boosted reimbursement for GraftAssureCore to $2,753 per result, establishing a strong benchmark for future kitted tests.
• Published strong head-to-head data favoring their digital PCR-based kits over widely used NGS kits, supporting marketing efforts.
• New data presented at the World Transplant Congress potentially sets a new bar for predicting graft rejection, reducing false positives and unnecessary biopsies.
• MolDx's draft LCD provides clarity on cfDNA surveillance testing reimbursement, aligning with the company's market estimates.
• First GraftAssureIQ RUO kit sales to a major European hospital validate the 'Land and Expand' strategy for future clinical kit sales.
• Began shipping optimized second-generation GraftAssureIQ kits, improving user experience and consolidating ease-of-use leadership.
• Positive demand trends from European conferences, with 70% of laboratory professionals requesting follow-up meetings.
• Signed a non-binding development letter of intent for the DetermaIO oncology assay, laying groundwork for strategic collaboration.
• Awarded a new patent for colorectal cancer detection, strengthening intellectual property in oncology.
• Gross margin expanded to 67.6% in Q2 2025 from 62% in Q1 2025, driven by operational efficiencies and amortized intangibles.
• Cash burn from operations and capital expenditures were generally in line with targeted quarterly average spend, demonstrating financial discipline.

Negatives

• Reported a net loss of $9.7 million and a non-GAAP loss from operations of $5.98 million in Q2 2025.
• Operating expenses increased sequentially (excluding non-cash charges) due to increased investment in the FDA program and sales/marketing ahead of commercial launch.
• Research and development expenses increased 12% sequentially to $3.3 million, reflecting higher investment in kitted product development.
• Sales and marketing expenses grew 21% sequentially to $1.5 million, indicating increased pre-commercialization spending.
• Intentional mitigation of RUO sales in the short term due to workflow improvements and customer validation of second-generation kits, impacting immediate revenue from this segment.
• The MolDx LCD is currently in draft form and subject to revision, introducing some uncertainty regarding final reimbursement policies.

Risks

• Inherent risks in the development and/or commercialization of diagnostic tests or products.
• Uncertainty in the results of clinical trials or regulatory approvals.
• The capacity of the third-party supplied blood sample analytic system to provide consistent and precise analytic results on a commercial scale.
• Potential interruptions to supply chains.
• The need and ability to obtain future capital.
• Maintenance of intellectual property rights in all applicable jurisdictions.
• Obligations to third parties with respect to licensed or acquired technology and products.
• The need to obtain third-party reimbursement for patients' use of any diagnostic tests.
• Risks inherent in strategic transactions, such as the potential failure to realize anticipated benefits.
• Legal, regulatory, or political changes in the applicable jurisdictions.
• Challenges related to accounting and quality controls.
• Potential greater than estimated allocations of resources to develop and commercialize technologies.
• Potential failure to maintain any laboratory accreditation or certification.

Future Outlook

The company is highly focused on concluding its clinical trial and submitting GraftAssureDx to the FDA by the end of 2025, with anticipated marketing authorization as soon as mid-2026. They expect no significant delays between trial close and FDA submission due to a templated data submission process. Beyond kidney, they foresee at least six potential areas for clinical and regulatory expansion of dd-cfDNA kitted assays from 2026 to 2028, including monitoring therapeutic response, recurrence monitoring, and expansion into heart, lung, and liver transplant testing. They are also building a scientific case for digital PCR's unique capabilities beyond current market offerings, potentially enabling new use cases for dd-cfDNA testing over the life of a kidney transplant patient, from early detection to therapeutic efficacy and recurrence monitoring.

Management Comments

• "We are closer than we have ever been to delivering a regulated kitted transplant monitoring assay to the market."
• "We continue to carefully manage our FDA data submission project and remain on track to submit our kitted test, GraftAssureDx, for FDA review by the end of this year, which is a reiteration of the timeline that we communicated in our March and May shareholder letters."
• "We continue to be encouraged by our productive dialogue with the FDA and our review team's sincere guidance and engagement."
• "It is our belief that if we do the hard work of designing a lab test in a kitted form and achieve regulatory authorization, then we will not only democratize access to these tests... but also create a rapidly growing, high-margin, recurring revenue business model."
• "While we have communicated that we do not expect material revenue on our kitted product sales until after we have achieved regulatory clearance to market GraftAssureDx, we nevertheless are pleased that a European transplant hospital customer purchased a small number of first-generation research-use-only kits in the quarter."
• "Our mission is to democratize access to molecular diagnostic testing to improve patient outcomes. We aim to lead in molecular diagnostics by doing what sets technology companies apart: developing proprietary algorithms that drive scalable value." (From CEO Josh Riggs' inaugural annual letter)
• "We believe that the data points regarding both absolute quantification as well as relative quantification are exciting."

Industry Context

The company operates in the molecular diagnostics market, specifically targeting transplant rejection testing and expanding into oncology. The strategic decision to pursue FDA authorization for kitted tests like GraftAssureDx is significant, as most complex molecular diagnostics tests in the U.S. have historically lacked FDA authorization, limiting market penetration and global accessibility. By seeking regulatory approval, iMDx aims to democratize access to these tests, enabling hospitals worldwide to run them in-house, which aligns with a broader industry trend towards decentralized, point-of-care diagnostics. The MolDx draft LCD for cfDNA surveillance testing indicates growing recognition and potential for broader reimbursement for these types of tests within the industry. The company's focus on digital PCR and its ability to combine relative and absolute dd-cfDNA measurements suggests an attempt to differentiate itself in a competitive landscape that includes NGS-based testing. Expansion into oncology, particularly non-invasive cancer detection, positions iMDx in another high-growth segment of the diagnostics market.

Comparison to Industry Standards

• The company's digital PCR-based test kits were favorably compared head-to-head with NGS kits, which are commercially available and widely used in the U.S., suggesting a competitive advantage in accuracy or utility for in-house hospital testing.
• Late-breaking data presented at the World Transplant Congress showed iMDx's digital PCR assay combining relative and absolute dd-cfDNA measurements into a single score, resulting in significantly improved positive predictive values and fewer false positives compared to existing methods. This potentially sets a new standard for predicting graft rejection in kidney transplant patients, reducing the need for invasive biopsies.
• MolDx's draft surveillance levels (four tests in the first year, two per year thereafter) for cfDNA tests align with iMDx's historical stated total addressable market and investment thesis, indicating that their market strategy is consistent with emerging industry reimbursement guidelines.
• The company's 'Land and Expand' strategy with research-use-only (RUO) kits, followed by clinical Dx kits, is a common approach in the diagnostics industry to build customer familiarity and adoption before full commercial launch.

Corporate Governance

Stakeholder Impact

• Shareholders: Positive impact from progress towards FDA approval, potential for high-margin recurring revenue, and expanded market opportunities. Negative impact from continued net losses and cash burn.
• Patients: Improved access to important molecular diagnostic tests, potentially fewer false positives and unnecessary invasive biopsies for transplant patients, and future expansion into other organ transplants and cancer detection.
• Hospitals/Labs: Empowerment to run tests themselves, expedient delivery of actionable results, potential for more sustainable operations, and ability to bring testing in-house.
• Employees: Continued investment in R&D and sales/marketing suggests growth and stability in those areas.
• Creditors: Financial health indicated by cash balance and managed cash burn, but ongoing losses suggest reliance on future revenue or capital.

Next Steps

• Conclude clinical trial for GraftAssureDx.
• Submit GraftAssureDx to the FDA for marketing authorization by the end of 2025.
• Begin marketing GraftAssureDx upon FDA authorization, as soon as mid-2026.
• Further evaluate the combined dd-cfDNA score in the ongoing FDA study (NCT07060716).
• Monitor the finalization of MolDx's draft LCD for surveillance testing.
• Drive additional GraftAssureIQ sales later this year as pilot sites validate the second-generation assay.
• Explore at least six potential areas for clinical and regulatory expansion of dd-cfDNA kitted assays from 2026 to 2028 (e.g., therapeutic response monitoring, recurrence monitoring, urine indications, heart, lung, and liver transplant testing).
• Publish future clinical data to build a scientific case for digital PCR's capabilities.
• Host a live Zoom Call and Webcast for Q2 2025 Earnings on August 11, 2025.
• Host a KOL Call on August 15, 2025, featuring Dr. Anthony Langone.

Key Dates

Recommendation

The company is making significant progress on its key strategic initiatives, particularly the FDA submission for GraftAssureDx and positive clinical data. The expansion of gross margins and managed cash burn are also favorable. However, the company is still pre-commercial for its primary kitted product and continues to incur substantial net losses. While the outlook is promising, the investment carries regulatory and commercialization risks, and material revenue is not expected until mid-2026. A 'hold' recommendation reflects the positive momentum balanced against the inherent risks and the time horizon for profitability.

Keywords

Molecular Diagnostics, Transplant Rejection, FDA Approval, GraftAssureDx, GraftAssureIQ, Oncology, Circulating Cell-Free DNA, dd-cfDNA, Digital PCR, Kidney Transplant, Cancer Detection, Immuno-oncology, Biotechnology, Clinical Trials, Reimbursement, Nasdaq, IMDX